6位分析师对Vir Biotechnology的共识为“适度买入”，12个月平均目标价为33美元。 6 analysts have a "Moderate Buy" consensus for Vir Biotechnology, with a $33 avg 12-month target price.

维尔生物技术公司 (NASDAQ:VIR) 拥有六位分析师的"适度购买"共识建议,平均12个月目标价格为33美元. Vir Biotechnology, Inc. (NASDAQ:VIR) has a "Moderate Buy" consensus recommendation from six analysts covering the firm, with an average 12-month target price of $33.00. 该公司专注于严重传染病的免疫学治疗，最近摩根士丹利（Morgan Stanley）、Needham&Company LLC、HC Wainwright、摩根大通（JPMorgan Chase & Co.）和巴克莱银行（Barclays）等券商调整了目标价。 The company, which focuses on immunology treatments for serious infectious diseases, has seen recent price target revisions from brokerages including Morgan Stanley, Needham & Company LLC, HC Wainwright, JPMorgan Chase & Co., and Barclays. 机构投资者拥有Vir生物技术库存的65.32%。 Institutional investors own 65.32% of Vir Biotechnology's stock.